| 1464 |
National Cancer Institute |
Html |
en |
Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of malignant mesothelioma. |
| standard treatment option | 0.662037 |
| relatively long survival | 0.763744 |
| definitive surgery | 0.66758 |
| advanced mesothelioma | 0.746687 |
| major symptomatic problems | 0.680779 |
| chemotherapy | 0.784047 |
| worst prognostic group | 0.744191 |
| sarcomatoid mesothelioma | 0.794135 |
| bland tumor cells | 0.677183 |
| recurrence-free survival | 0.667934 |
| clinical trials | 0.794592 |
| important prognostic factor. | 0.728634 |
| Median survival | 0.786141 |
| randomized study | 0.677593 |
| patients | 0.897231 |
| survival | 0.852167 |
| useful immunohistochemical stains | 0.67583 |
| CALGB prognostic group | 0.748668 |
| progression-free survival rate | 0.733148 |
| Cooperative Oncology Group | 0.690912 |
| neoadjuvant chemotherapy | 0.666321 |
| survival times | 0.760237 |
| prognostic value | 0.740005 |
| radiation therapy | 0.723289 |
|
| improved survival | 0.661891 |
| poorer survival | 0.696893 |
| aggressive treatment approaches | 0.668925 |
| different treatment modalities | 0.670393 |
| aggressive surgical approaches | 0.806279 |
| CALGB index | 0.684276 |
| mesothelioma diagnoses. | 0.716989 |
| Desmoplastic mesothelioma | 0.719754 |
| epithelioid mesothelioma | 0.727094 |
| adjuvant radiation therapy | 0.676072 |
| mesothelioma | 0.925011 |
| Advanced Malignant Mesothelioma | 0.78476 |
| tissue specimens | 0.675675 |
| malignant pleural mesothelioma | 0.822532 |
| first-line chemotherapy | 0.674756 |
| white blood cell | 0.694326 |
| first-line combination chemotherapy | 0.748058 |
| recurrent malignant mesothelioma | 0.883067 |
| extrapleural pneumonectomy | 0.673182 |
| malignant pleural disease | 0.743809 |
| large randomized study | 0.671727 |
| PDQ summary | 0.685413 |
| improved long-term survival | 0.756886 |
| prognostic groups | 0.660571 |
|
CLICK HERE |
| 1727 |
National Cancer Institute |
Html |
en |
Bone Cancer |
A fact sheet about the diagnosis and treatment of cancers that develop in the bones. |
| benign bone tumors | 0.382978 |
| soft tissue | 0.317275 |
| osteoid tissue | 0.26524 |
| uncommon cancer | 0.255981 |
| primary bone cancer | 0.577561 |
| cancer cells | 0.329155 |
| abnormal bone tissue | 0.376855 |
| metastatic cancer | 0.262213 |
| bone scan | 0.325169 |
| anticancer drugs | 0.274172 |
| Cancer Information Service | 0.273277 |
| Yes. Cancer | 0.261575 |
| tumor causes production | 0.259064 |
| healthy bone tissue | 0.408981 |
| Yes. Bone cancer | 0.36265 |
| Cancer Treatment Research | 0.2781 |
| preoperative tumor treatment | 0.265675 |
| healthy tissue | 0.254742 |
| fibrous tissue | 0.263622 |
| clinical trials | 0.344137 |
| bone tissue | 0.452141 |
| primitive nerve tissue | 0.285777 |
| heredity cancer syndromes | 0.279206 |
| normal bone tissue | 0.410848 |
|
| Clinical Trials page | 0.251984 |
| Ewing Sarcoma Family | 0.249697 |
| soft tissue sarcomas | 0.285733 |
| incisional biopsy | 0.250026 |
| tissue sample | 0.258655 |
| blood vessels | 0.251489 |
| high-dose external radiation | 0.249703 |
| spongy tissue | 0.268691 |
| bone marrow | 0.344367 |
| cancer centers | 0.251332 |
| different types | 0.282598 |
| doctor | 0.249686 |
| new bone cells | 0.361397 |
| bones | 0.259461 |
| important treatment option | 0.251744 |
| radiation therapy | 0.277888 |
| treatment options | 0.263715 |
| bone cancer | 0.911469 |
| comprehensive cancer information | 0.27281 |
| research studies | 0.263781 |
| cancerous bone cells | 0.36956 |
| bone cancers | 0.35903 |
| African American children | 0.253491 |
|
CLICK HERE |
| 1773 |
National Cancer Institute |
Html |
es |
Trastornos del sueño (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las causas de los trastornos del sueño de las personas con cáncer y su manejo. |
| American Academy | 0.62007 |
| sleep disturbance | 0.546203 |
| Sateia MJ | 0.426893 |
| Sleep Disturbance Scale | 0.434259 |
| CdV Mejoras | 0.428861 |
| mg riesgo | 0.50361 |
| National Sleep Foundation | 0.473914 |
| Sleep Quality Index | 0.466452 |
| Simard S | 0.452533 |
| neglected problem | 0.428741 |
| sueño mor | 0.943385 |
| risk factors | 0.426951 |
| sleep-wake disturbances | 0.458084 |
| Sleep Disorders | 0.45951 |
| Oncol Nurs | 0.45478 |
| PDQ Delirium | 0.436712 |
| coordinación motriz | 0.436956 |
| sueño diario | 0.570793 |
| sleep disruption | 0.458489 |
| Insomnia Severity Index | 0.446987 |
| patients with | 0.455594 |
| Hirshkowitz M | 0.42487 |
| Pittsburgh Sleep Quality | 0.464939 |
| Insomnia Severity | 0.454434 |
| sueño frente | 0.501612 |
|
| Roscoe JA | 0.426353 |
| Oncol Nurs Forum | 0.453234 |
| Morin CM | 0.426813 |
| sueño categorÃa | 0.493243 |
| Care Cancer | 0.439262 |
| Palesh OG | 0.427427 |
| ECA Control | 0.495325 |
| Savard J | 0.54747 |
| Sleep Medicine review | 0.435342 |
| Mustian KM | 0.426387 |
| patients based | 0.427546 |
| Rochester Cancer Center-Community | 0.462263 |
| Clinical Oncology Program | 0.450218 |
| sleep regulation | 0.427006 |
| sueño nmor | 0.697198 |
| Clin Oncol | 0.506515 |
| Clin North Am | 0.455007 |
| estadio i–iii | 0.467766 |
| Center-Community Clinical Oncology | 0.451231 |
| psychological associations | 0.42745 |
| Cancer Center-Community Clinical | 0.464249 |
| Sleep Medicine | 0.709305 |
| Med Clin North | 0.456379 |
| Sleep Disorders Classification | 0.439634 |
|
CLICK HERE |
| 1889 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de colon (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon. |
| siguientes procedimientos | 0.92972 |
| pequeña cantidad | 0.497446 |
| estadio ii | 0.856655 |
| tubo recolector | 0.46569 |
| rayos x | 0.562684 |
| inferior.ampliar procedimiento | 0.480242 |
| enlace drugs approved | 0.587222 |
| escáner tep | 0.457465 |
| proteÃna llamada factor | 0.458005 |
| National Cancer Institute | 0.432943 |
| sustancia llamada gadolinio | 0.497309 |
| siguientes riesgos | 0.425516 |
| Instituto Nacional | 0.460477 |
| PDQ Tratamiento | 0.671072 |
| estadio iiia | 0.656788 |
| antecedentes familiares | 0.459139 |
|
| estadio iiic | 0.63832 |
| cáncer.ampliar sigmoidoscopia | 0.46788 |
| estadio iiib | 0.647408 |
| estadio iia | 0.819513 |
| estadio iic | 0.81663 |
| células cancerosas.El bevacizumab | 0.49983 |
| Physician Data Query | 0.524312 |
| Rectal Cancer | 0.499997 |
| cuerpo).ampliar anatomÃa | 0.468805 |
| crecer.El ziv-aflibercept | 0.437476 |
| antÃgeno carcinoembrionario | 0.577035 |
| PDQ Cánceres | 0.540215 |
| colon forma | 0.990115 |
| tejidos sanos circundantes | 0.470011 |
| Estadio IVA | 0.522216 |
| siguientes pruebas | 0.469066 |
|
CLICK HERE |
| 1995 |
National Cancer Institute |
Html |
es |
Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el tratamiento de la histiocitosis de células de Langerhans infantil. |
| Immunol Cell Biol | 0.40642 |
| langerhans cell | 0.852012 |
| lesiones hcl | 0.406571 |
| with langerhans | 0.417161 |
| langerhans cell histiocytosis | 0.986891 |
| multisystem langerhans | 0.422209 |
| BRAF V600E-negative Langerhans | 0.406114 |
| Langerhans-cell histiocytosis | 0.403191 |
| cutaneous langerhans | 0.405301 |
| células dendrÃticas mieloides | 0.413633 |
| BRAF Mutation Correlates | 0.403764 |
| braf mutation | 0.404571 |
| pulmonary langerhans | 0.409447 |
| pediatric-onset multisystem langerhans | 0.405705 |
| HCL multisistémica | 0.436981 |
| pulmonary langerhans cell | 0.407403 |
| Grois N | 0.403041 |
| cell histiocytosis patients | 0.407759 |
| Cell Histiocytosis Study | 0.404713 |
| cell histiocytosis harboring | 0.404154 |
| mutación v600e | 0.406931 |
| dendritic cell differentiation | 0.403188 |
| mutación braf v600e | 0.411753 |
| histiocytosis lesions reveals | 0.403971 |
| Arch Dis Child | 0.403576 |
|
| Emile JF | 0.403241 |
| epidermal langerhans cells | 0.412171 |
| HCL dérmica | 0.409229 |
| BRAF V600E | 0.436151 |
| Pediatr Blood Cancer | 0.419983 |
| lesiones óseas | 0.406722 |
| With High-Risk Langerhans | 0.411149 |
| mutaciones braf v600e | 0.404471 |
| Multiresistant Langerhans Cell | 0.407509 |
| mutación braf | 0.412372 |
| braf inhibitor | 0.402661 |
| Med Pediatr Oncol | 0.402927 |
| Clin Oncol | 0.402664 |
| with braf | 0.403023 |
| células circulantes | 0.409275 |
| adult pulmonary langerhans | 0.405666 |
| HCL CD1a-positivas | 0.409797 |
| Langerhans'-cell histiocytosis | 0.405031 |
| High-Risk Langerhans Cell | 0.421727 |
| oncogén braf | 0.403238 |
| tratamiento inicial.la hcl | 0.405836 |
| with epidermal langerhans | 0.411581 |
| childhood langerhans | 0.408867 |
| French Langerhans | 0.405677 |
|
CLICK HERE |
| 3446 |
National Cancer Institute |
Html |
es |
Consumo de cigarrillo: riesgos para la salud y cómo dejar de fumar (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre la investigación y pautas que se enfocan en la prevención y el abandono del tabaquismo. |
| efectos secundarios comentarios | 0.501986 |
| leucemia mieloide | 0.427415 |
| metabolitos carcinógenos | 0.42791 |
| bupropión marca dosis | 0.454219 |
| grupo vareniclina | 0.463468 |
| importancia clÃnica | 0.450606 |
| MVL Nicorette DS | 0.439222 |
| pruebas directas | 0.619014 |
| MVL Nicoderm CQ | 0.440426 |
| MVL Commit | 0.42718 |
| Sin embargo | 0.467903 |
| muertes prematuras | 0.469229 |
| largo plazo | 0.764238 |
| cessation interventions among | 0.449671 |
| Lung Health Study | 0.44169 |
| Lancaster T | 0.545862 |
| defunciones prematuras | 0.434559 |
| bupropión mejora | 0.45245 |
| Stead LF | 0.482703 |
| orientación mejora | 0.429664 |
| bupropión ap | 0.446903 |
| Nicotine replacement therapy | 0.444158 |
| semanas insomnio | 0.443481 |
| vareniclina mejora | 0.477582 |
| Estados Unidos | 0.989049 |
|
| polacrilex marca dosis | 0.434801 |
| insomnio riesgo | 0.427937 |
| smoking cessation | 0.872626 |
| salud pública | 0.590985 |
| Database Syst Rev | 0.689429 |
| abandono gradual versus | 0.477395 |
| nicotina marca dosis | 0.473496 |
| beneficio hipotético implÃcito | 0.443214 |
| Treating Tobacco Use | 0.44172 |
| versus trn | 0.451335 |
| MVL Nicorette | 0.462807 |
| mejores tasas | 0.435725 |
| Community Intervention Trial | 0.530278 |
| Marca Dosis Efectos | 0.591077 |
| alta calidad | 0.516955 |
| efectos secundarios advertencias | 0.436485 |
| compuestos carcinógenos | 0.426773 |
| tasas promedio | 0.433836 |
| aductos carcinógenos | 0.42846 |
| planta cytisus laburnum | 0.434664 |
| antidepresivo bupropión | 0.449342 |
| cuello uterino | 0.576293 |
| MVL Nicotrol | 0.425887 |
| Surveillance Modeling Network | 0.440037 |
|
CLICK HERE |
| 3573 |
National Cancer Institute |
Html |
en |
Immunotherapy: Using the Immune System to Treat Cancer |
Immunotherapies are treatments that restore or enhance the immune system’s natural ability to fight cancer. In just the past few years, the rapidly advancing field of cancer immunology has produced several new methods of treating cancer that increase the strength of immune responses against tumors. |
| abnormal cells | 0.352853 |
| CAR T cells | 0.324531 |
| cancer cells | 0.817652 |
| immune system activity | 0.227645 |
| immune responses | 0.409806 |
| toxic substance | 0.204832 |
| dendritic cells | 0.272111 |
| immune system molecules | 0.223265 |
| white blood cells | 0.307219 |
| activated T cells | 0.296761 |
| immune system—research | 0.253725 |
| immune response | 0.250155 |
| advanced lung cancer | 0.212796 |
| cancer treatment vaccine | 0.201283 |
| clinical trials | 0.278634 |
| tumor cells | 0.49599 |
| CD20-expressing cells | 0.269956 |
| normal cells | 0.295119 |
| human clinical trials | 0.248944 |
|
| antibody-dependent cell-mediated cytotoxicity | 0.250246 |
| patients | 0.23385 |
| advanced melanoma | 0.22903 |
| immune cells | 0.680701 |
| immune checkpoint inhibitors | 0.313495 |
| FDA-approved checkpoint inhibitors | 0.216978 |
| therapeutic antibodies | 0.216622 |
| cancer cell death | 0.250231 |
| immunotherapy uses proteins | 0.212508 |
| CAR T-cell therapy | 0.397055 |
| natural killer cells | 0.304861 |
| lymphoma cells | 0.266327 |
| cells | 0.903811 |
| different checkpoint protein | 0.207351 |
| modified T cells | 0.282987 |
| immune checkpoint proteins | 0.3798 |
| existing T cells | 0.321978 |
| certain immune cells | 0.38886 |
|
CLICK HERE |
| 16203 |
National Cancer Institute |
Html |
en |
Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer |
A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. |
| Novartis Pharmaceuticals | 0.50861 |
| M.D. | 0.440705 |
| Postmenopausal women | 0.52856 |
| control group | 0.563284 |
| second-line therapy | 0.517854 |
| proteins—cyclin-dependent kinase | 0.519068 |
| CDK4/6 inhibitor | 0.52299 |
| Gabriel N. Hortobagyi | 0.621331 |
| ribociclib arm | 0.512946 |
| median follow-up | 0.54408 |
| significantly more neutropenia | 0.507111 |
| overall survival | 0.538115 |
| Alexandra Zimmer | 0.526907 |
| greater share | 0.502287 |
| infections | 0.43551 |
| Cancer Research | 0.512142 |
| first-line treatment | 0.673992 |
| tumor cells | 0.508198 |
| median progression-free survival | 0.787416 |
| clinical trial | 0.51962 |
| significant benefit | 0.498831 |
| letrozole | 0.459254 |
| ribociclib group | 0.78322 |
| first-line therapy | 0.552793 |
|
| disease | 0.421331 |
| MD Anderson Cancer | 0.627314 |
| progression-free survival | 0.953616 |
| placebo group | 0.714241 |
| careful monitoring | 0.503418 |
| patients | 0.470449 |
| planned interim analysis | 0.594125 |
| adverse events | 0.50283 |
| improvement | 0.435679 |
| Medicine | 0.420889 |
| higher rate | 0.49447 |
| NCI’s Center | 0.505585 |
| University | 0.421021 |
| favor | 0.420251 |
| HER2-negative metastatic breast | 0.65043 |
| certain types | 0.509753 |
| Texas | 0.421011 |
| metastatic breast cancer | 0.821955 |
| colleagues | 0.422295 |
| New England Journal | 0.621204 |
| HER2-negative breast cancer | 0.726717 |
| Femara® | 0.421383 |
| Dr. Zimmer | 0.591472 |
|
CLICK HERE |
| 16637 |
National Cancer Institute |
Html |
en |
Metformin: Can a Diabetes Drug Help Prevent Cancer? |
An article about the diabetes drug metformin, which research suggests may help prevent cancer. |
| metformin derivative | 0.623089 |
| cancer treatment | 0.490275 |
| study participants | 0.484909 |
| Dr. Heckman-Stoddard | 0.535865 |
| Family Comprehensive Cancer | 0.513801 |
| metformin arm | 0.64832 |
| early-phase prevention trials | 0.505251 |
| substantially lower risk | 0.487063 |
| original metformin formulation | 0.653789 |
| extensive laboratory research | 0.487291 |
| conventional antidiabetic doses | 0.482196 |
| Phase Prevention Trials | 0.510585 |
| clinical trials | 0.598194 |
| DPP Outcomes Study | 0.570815 |
| early-stage breast cancer | 0.516459 |
| laboratory studies | 0.518492 |
| Cancer Center | 0.508828 |
| Dr. Pollak | 0.522365 |
| triple-negative breast cancer | 0.514736 |
| postmenopausal breast cancer | 0.520249 |
| Dr. Zell | 0.51558 |
| cancer survivors | 0.511148 |
| Diego Moores Cancer | 0.510708 |
| metformin treatment | 0.637604 |
| large epidemiologic studies | 0.500626 |
|
| breast cancer cells | 0.511965 |
| cancer prevention | 0.554231 |
| primary cancer | 0.48954 |
| certain blood biomarkers | 0.485052 |
| cancer outcomes | 0.485417 |
| metformin derivatives | 0.623142 |
| blood biomarkers | 0.487459 |
| smaller prevention trials | 0.498934 |
| metformin | 0.934872 |
| breast cancer | 0.751317 |
| metformin’s effect | 0.638135 |
| cancer development | 0.510096 |
| early-stage clinical trials | 0.564264 |
| metformin’s impact | 0.702491 |
| breast cancer recurrences | 0.517045 |
| cancer clinical trials | 0.527071 |
| Diabetes Prevention Program | 0.513336 |
| cancer risk | 0.512957 |
| early-phase clinical trial | 0.492505 |
| cancer | 0.791776 |
| prevention trials | 0.556708 |
| diabetes drug metformin | 0.743736 |
| cancer incidence | 0.513399 |
| Antonio Breast Cancer | 0.515009 |
|
CLICK HERE |
| 16859 |
National Cancer Institute |
Html |
en |
Annual Reporting and Auditing |
Reporting helps ensure desired results are achieved throughout the grants lifecycle. Learn more about reporting and auditing requirements for cancer research grants. |
| audit requirements | 0.743431 |
| expenditure data | 0.682542 |
| recipient organization | 0.553305 |
| Interagency Edison | 0.55337 |
| specific grant | 0.551262 |
| budget period | 0.798124 |
| frequent reporting | 0.683485 |
| GPO Stock | 0.544524 |
| foreign organizations | 0.54552 |
| competing project period | 0.68277 |
| federal government | 0.548657 |
| management staff review | 0.661754 |
| federal support | 0.55664 |
| Financial operations | 0.549474 |
| for-profit hospitals | 0.543055 |
| financial expenditure reports | 0.726911 |
| NIH Grants Policy | 0.987592 |
| financial status | 0.557124 |
| NCI Program | 0.553741 |
| cash transaction data | 0.661127 |
| For-profit organizations | 0.556895 |
| individual award requirements | 0.714539 |
| recipient organizations | 0.564783 |
| multiple PIs | 0.556136 |
| award process | 0.560959 |
|
| grants management staff | 0.941167 |
| common reports | 0.590648 |
| recipients | 0.59377 |
| annual basis | 0.550363 |
| annual reports | 0.571527 |
| grant award | 0.582091 |
| different schedule | 0.553636 |
| Contact PI | 0.548816 |
| federal awards | 0.687649 |
| local government audit | 0.75977 |
| progress report | 0.54964 |
| subsequent budget period | 0.690671 |
| eRA Commons | 0.887345 |
| grant activity | 0.54536 |
| annual audit | 0.999887 |
| official accounting records | 0.673267 |
| nonprofit organizations | 0.546576 |
| NIH support | 0.566195 |
| non-competing continuation | 0.568684 |
| Financial reports | 0.562828 |
| generally accepted government | 0.654669 |
| government auditing standards | 0.89142 |
| Grants Policy Statement | 0.964206 |
| financial related audit | 0.753867 |
|
CLICK HERE |